Sunday , June 24 2018
Home / Paul Chous, M.A., O.D.

Paul Chous, M.A., O.D.

Paul Chous, M.A., O.D.
(Advisory Board Member) Dr. Paul Chous received his undergraduate education at Brown University and the University of California at Irvine, where he was elected to Phi Beta Kappa in 1985. He received his Masters Degree in 1986 and his Doctorate of Optometry in 1991, both with highest honors from the University of California at Berkeley. Dr. Chous has practiced optometry with a special emphasis on diabetic eye disease and diabetes education for 20 years in the State of Washington, winning the American Diabetes Association’s Distinguished Public Service Award in 1998.

Counterpoint: The Pros and Cons of AI-based “Diagnosis” of Diabetic Retinopathy

By A. Paul Chous, MA, OD, FAAO, CDE

The FDA just gave first approval to an artificial intelligence (AI) algorithm for the detection of diabetic retinopathy in the offices of non-ophthalmic health care practitioners. Dubbed the IDx-DR (IDx, LLC, Coralville, Iowa), and paired with a Topcon NW400 non-mydriatic retinal camera, captured images are sent to a cloud-based server that utilizes the IDx-DR software and a ‘deep learning’ algorithm to detect retinal findings consistent with diabetic retinopathy based on autonomous comparison with a large dataset of representative fundus images.

Read More »

2017 ADA Position Statement on Diabetic Retinopathy

This represents the first such update by the American Diabetes Association since 2002, and is notable for inclusion of the latest evidence and recommendations with respect to appropriate eye examination intervals, referral criteria, prevention of incidence and progression of diabetic retinopathy (DR), and treatment strategies.

Read More »

Do Supplements Help Diabetes Vision?

Protection of visual function may signal disruption of mechanisms underlying diabetic retinopathy (DR)… This was a 6-month randomized, controlled clinical trial of patients with type 1 and type 2 diabetes with no retinopathy or mild to moderate non-proliferative retinopathy assigned to twice-daily consumption of placebo or a novel, multi-component formula …

Read More »